AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

Core Insights - AIM ImmunoTech Inc. reported positive mid-year data from the Phase 2 DURIPANC study, indicating promising signs of no significant toxicity and superior progression-free survival (PFS) and overall survival (OS) in metastatic pancreatic cancer patients treated with Ampligen® and durvalumab [1][3][5] Company Overview - AIM ImmunoTech is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, with Ampligen® being its lead investigational drug [9] Study Details - The DURIPANC study is a collaboration with AstraZeneca and Erasmus Medical Center, aiming to evaluate the combination therapy of Ampligen and durvalumab in patients with stable disease post-FOLFIRINOX [1][4] - The study is expected to enroll up to 25 subjects, with 14 subjects enrolled as of the mid-year report [1] Preliminary Findings - The combination therapy has shown a well-tolerated safety profile, with approximately 21% of patients experiencing PFS greater than 6 months and 64% of eligible patients having OS greater than 6 months [5] - The study aims to assess clinical benefit rates, OS, PFS, and initiate immune-monitoring using tissue biopsies and immune profiling [1][2] Future Directions - Further analysis of immune-monitoring data is anticipated to provide insights into the biological activity and durability of response, as well as identify predictive biomarkers for patient selection [2][3] - The company has developed an intellectual property plan, including a U.S. patent for Ampligen as an oncology treatment, extending protection to August 9, 2039 [8]